AIM: The aim of this study was to investigate the effects of co-medication with selective serotonin re-uptake inhibitors (SSRIs) on overanticoagulation during acenocoumarol maintenance treatment. METHODS: All subjects from The Rotterdam Study who received acenocoumarol maintenance treatment between April 1 1991 and September 9 2009 were followed for the event of an international normalized ratio (INR) ≥6, until death, end of treatment or end of the study period. With the Andersen-Gill extension of the Cox proportional hazards model, risks for repeated events of overanticoagulation in relation to concomitant SSRI use were calculated. RESULTS: The risk for overanticoagulation during acenocoumarol maintenance treatment was increased in combination with fluvoxamine (HR 2.63, 95% CI 1.49, 4.66) and venlafaxine (HR 2.19, 95% CI 1.21, 3.99). There was no increase in risk for the other SSRIs, but numbers of exposed cases were low for all SSRIs except paroxetine. CONCLUSION: Fluvoxamine and venlafaxine were associated with a more than double risk of INR values ≥6 in acenocoumarol treated subjects.
AIM: The aim of this study was to investigate the effects of co-medication with selective serotonin re-uptake inhibitors (SSRIs) on overanticoagulation during acenocoumarol maintenance treatment. METHODS: All subjects from The Rotterdam Study who received acenocoumarol maintenance treatment between April 1 1991 and September 9 2009 were followed for the event of an international normalized ratio (INR) ≥6, until death, end of treatment or end of the study period. With the Andersen-Gill extension of the Cox proportional hazards model, risks for repeated events of overanticoagulation in relation to concomitant SSRI use were calculated. RESULTS: The risk for overanticoagulation during acenocoumarol maintenance treatment was increased in combination with fluvoxamine (HR 2.63, 95% CI 1.49, 4.66) and venlafaxine (HR 2.19, 95% CI 1.21, 3.99). There was no increase in risk for the other SSRIs, but numbers of exposed cases were low for all SSRIs except paroxetine. CONCLUSION:Fluvoxamine and venlafaxine were associated with a more than double risk of INR values ≥6 in acenocoumarol treated subjects.
Authors: Loes E Visser; Ron H N van Schaik; Martin van Vliet; Paul H Trienekens; Peter A G M De Smet; Arnold G Vulto; Albert Hofman; Cornelia M van Duijn; Bruno H Ch Stricker Journal: Clin Pharmacol Ther Date: 2005-06 Impact factor: 6.875
Authors: Elizabeth A Sconce; Tayyaba I Khan; Hilary A Wynne; Peter Avery; Louise Monkhouse; Barry P King; Peter Wood; Patrick Kesteven; Ann K Daly; Farhad Kamali Journal: Blood Date: 2005-06-09 Impact factor: 22.113
Authors: Welmoed E E Meijer; Eibert R Heerdink; Willem A Nolen; Ron M C Herings; Hubert G M Leufkens; Antoine C G Egberts Journal: Arch Intern Med Date: 2004-11-22
Authors: Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij Journal: Eur J Epidemiol Date: 2013-11-21 Impact factor: 8.082
Authors: Gene R Quinn; Daniel E Singer; Yuchiao Chang; Alan S Go; Leila H Borowsky; Natalia Udaltsova; Margaret C Fang Journal: Am J Cardiol Date: 2014-06-05 Impact factor: 2.778
Authors: Gene R Quinn; Anne S Hellkamp; Graeme J Hankey; Richard C Becker; Scott D Berkowitz; Günter Breithardt; Maurizio Fava; Keith A A Fox; Jonathan L Halperin; Kenneth W Mahaffey; Christopher C Nessel; Manesh R Patel; Jonathan P Piccini; Daniel E Singer Journal: J Am Heart Assoc Date: 2018-08-07 Impact factor: 5.501